4 results match your criteria: "From the Jiangsu Provincial Center for Disease Control and Prevention.[Affiliation]"
Background: A significant surge in pertussis cases since early 2023 has raised serious public health concerns. To investigate the potential mechanisms contributing to this increased prevalence, we collected throat swab specimens from children exhibiting pertussis symptoms and conducted detailed molecular characterization.
Methods: All Bordetella pertussis (B.
Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine Administered in a 3 + 1 versus 2 + 1 Dose Schedule Among Infants in China.
Pediatr Infect Dis J
November 2019
Pfizer Vaccine Clinical Research and Development, Pfizer Inc, Collegeville, Pennsylvania.
Background: 13-valent pneumococcal conjugate vaccine (PCV13) was licensed in China based on immunologic noninferiority to 7-valent PCV (PCV7). As part of the noninferiority study, immunogenicity and safety of PCV13 administered as a 3- or 2-dose infant series followed by a toddler dose were examined in healthy Chinese infants.
Methods: Infants (42- to 77-days-old) were randomized to a 3-dose PCV13 or PCV7 infant series administered double-blind at 3, 4 and 5 months or PCV13 administered open-label at 2, 4 and 6 months and a 2-dose open-label series at 3 and 5 months; all subjects received a toddler dose (12 months).
Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Compared With 7-valent Pneumococcal Conjugate Vaccine Among Healthy Infants in China.
Pediatr Infect Dis J
September 2016
From the *Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, People's Republic of China; †Division of Respiratory Bacterial Vaccines, NIFDC, Beijing, People's Republic of China; ‡Pfizer Vaccine Research, Collegeville, Pennsylvania; §Pfizer Vaccine Research, Shanghai, People'
Background: Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) were compared with 7-valent pneumococcal conjugate vaccine (PCV7) in Chinese infants.
Methods: Healthy infants aged 2 months were randomized to a double-blind 3-dose infant series plus 1 toddler dose of PCV7 or PCV13 at 3, 4, 5 and 12 months or open-label PCV13 at 2, 4, 6 and 12 months. Serotype-specific immunoglobulin G (IgG) binding and functionality were measured 1 month after the infant series and after the toddler dose.
Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China.
N Engl J Med
February 2014
From the Jiangsu Provincial Center for Disease Control and Prevention, Nanjing (F.Z., X.Z., Yuemei Hu, Q.L., J.L., S.W., H.W.); National Institutes for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (W.X., X.T., T.J., B.Z.), National Institutes for Food and D
Background: Enterovirus 71 (EV71) is one of the major causative agents of outbreaks of hand, foot, and mouth disease or herpangina worldwide. This phase 3 trial was designed to evaluate the efficacy, safety, and immunogenicity of an EV71 vaccine.
Methods: We conducted a randomized, double-blind, placebo-controlled, multicenter trial in which 10,007 healthy infants and young children (6 to 35 months of age) were randomly assigned in a 1:1 ratio to receive two intramuscular doses of either EV71 vaccine or placebo, 28 days apart.